Neuroprotective effects of oral administration of triacetyluridine against MPTP neurotoxicity

NeuroMolecular Medicine

Volumn 6, Issue 2-3, 2004, Pages 87-92

  Klivenyi, Peter ^a   Gardian, Gabrielle ^a   Calingasan, Noel Y ^a   Yang, Lichuan ^a   Von Borstel, Reid ^b   Saydoff, Joel ^b   Browne, Susan E ^a   Beal, M Flint ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Wellstat Therapeutics Corporation   (United States)

Author keywords

Dopamine; Mitochondria; MPTP; Parkinson's disease; Triacetyluridine

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; TRIACETYLURIDINE; UNCLASSIFIED DRUG; URIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DEGENERATIVE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; MOUSE; NERVE CELL; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SUBSTANTIA NIGRA;

ANIMALIA;

EID: 24644518083     PISSN: 15351084     EISSN: None     Source Type: Journal    
DOI: 10.1385/nmm:6:2-3:087     Document Type: Article

References (19)

1. Aussedat J. (1983) Effect of uridine supply on glycogen resynthesis after ischaemia in the isolated perfused rat heart. Cardiovasc. Res. 17, 145-151.
2. Beal M. F. (2001) Experimental models of Parkinson's disease. Nat. Rev. Neurosci. 2, 325-334.
3. 10 attenuates the 1-methyl-4-phenyl-1,2,3, tetrahydropyridine (MPTP) induced loss of striatal dopamine axons in aged mice. Brain Res. 157, 142-149.
4. Beuneu C., Auger R., Loffler M., Guissani A., Lemaire G., and Lepoivre M. (2000) Indirect inhibition of mitochondrial dihydroorotate dehydrogenase activity by nitric oxide. Free Radic. Biol. Med. 28, 1206-1213.
5. Connolly G. P. and Duley J. A. (1999) Uridine and its nucleotides: biological actions, therapeutic potentials. Trends Pharmacol. Sci. 20, 218-225.
6. Cornford E. M. and Oldendorf W. H. (1975) Independent blood-brain barrier transport systems for nucleic acid precursors. Biochim. Biophys. Acta 394, 211-219.
7. Forman J. H. and Kennedy J. (1975) Superoxide production and electron transport in mitochondrial oxidation of dihydroorotic acid. J. Biol. Chem. 250, 4322-4326.
8. Garcia R. A. G., Hu Z. Y., Liu L. S., Noble M., von Borstel R. W., and Saydoff J. A. (2002) Neuroprotective doses of PN401 that produce supraphysiological levels of uridine are greater than the dose of PN401 required to correct a pyrimidine deficiency. Soc. Neurosci. 27, 685.615.
9. Geiger A. and Yamasaki S. (1956) Cytidine and uridine requirement of the brain. J. Neurochem. 18, 93-100.
10. Hogans A. F., Guroff G., and Udenfriend S. (1971) Studies on the origin of pyrimidines for biosynthesis of neural RNA in the rat. J. Neurochem. 18, 1699-1710.
11. Horvath T. L., Diano S., Leranth C., et al. (2003) Coenzyme Q introduces nigral mitochondrial upcoupling and prevents dopamine cell loss in a primate model of Parkinson's disease. Endocrinology 144, 2757-2760.
12. Kelsen D. P., Martin D., O'Neil J., et al. (1997) Phase 1 trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer. J. Clin. Oncol. 15, 1511-1517.
13. King M. P. and Attardi G. (1989) Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science 246, 500-503.
14. Lin Z., Richards S., Rosenfeldt F., and Pepe S. (1997) Uridine preserves ATP during hypoxic perfusion of the rat heart. Asia Pac. Heart 6, 190-196.
15. Loffler M., Jockel J., Schuster G., and Becker C. (1997) Dihydroorotate-ubiquinone oxidoreductase links mitochondria in the biosynthesis of pyrimidine nucleotides. Mol. Cell Biochem. 174, 125-129.
16. Matthews R. T., Ferrante R. J., Klivenyi P., et al. (1999) Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp. Neurol. 157, 142-149.
17. Saydoff J. A., Liu L. S., Garcia R. A. G., Hu Z., Li D., and von Borstel R.W. (2003) Oral uridine pro-drug PN401 decreases neurodegeneration, behavioral impairment, weight loss and mortality in the 3-nitropropionic acid mitochondrial toxin model of Huntington's Disease. Brain Res. 994, 44-54.
18. Saydoff J. A., Liu L. S., Hu Z. Y., et al. (2001) Oral uridine Pro-drug P N 401 protects against azide toxicity in vivo: studies on the mechanism of uridine neuroprotection in vitro. Soc. Neurosci. 27, 2360.
19. Tieu K., Perier C., Caspersen C., et al. (2003) D-β Hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. J. Clin. Invest. 112, 892-901.